Jesse Shoplock is SVP of Business Development at Inbox Health. They are trying to help one of the messiest parts of American health care, figuring out both how much patients owe at the point of care and how to actually help the providers get paid. As of now 70% of patients don’t know what they…
Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of the employer GLP-1 platform eMed Population Health, were at SXSW drawing a contrast between their approach to GLP-1 drugs and that of other direct-to-consumer companies. They also announced a collaboration where Cost Plus Drugs will be eMed’s distribution partner. The post At SXSW,…
Isaac Health launched an eight-week virtual program to help people reduce dementia risk through lifestyle changes like sleep, nutrition and exercise. The post Isaac Health Introduces New Virtual Program to Reduce Dementia Risk appeared first on MedCity News.
Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence. The post FDA Drug Approval Marks a First for a Disease — But It’s Not Autism appeared first on MedCity…
L.A. County’s Shayan Rab, M.D., describes how street psychiatry has been integrated with specialty field-based mental health services and acute care settings
Florian Otto, CEO and co-founder of Cedar, says the company initially focused on transparency and convenience, but now also addresses affordability for patients
Epic has unveiled its new “agent factory,” a platform that lets health systems build AI agents that are capable of orchestrating entire workflows across the EHR. The post Epic Is Letting Health Systems Build Their Own Agents — But Are They Ready? appeared first on MedCity News.
Congress has already granted the FDA flexibility in evaluating therapies for rare diseases, including the use of real-world evidence and natural history data when traditional large-scale trials are not feasible. The question before the FDA now is not if those tools can be applied – they can – but if the agency has the courage…
For patients, recalls can fail to protect them — not because they came too late, but because they stop at notification and never fully translate into action. The post When Recalls Fail — The Gap Between Notification and Action appeared first on MedCity News.